ADME/Tox Technologies

 Table of Content
1. SCOPE AND METHODOLOGY	1
2. REPORT SYNOPSIS	4
ADME/Tox Technologies	4
Absorption	4
Distribution	4
Metabolism	4
Excretion	5
Toxicity	5
2.2 Significant Methods for ADME/Tox	5
Predictive Technologies	5
Related ADME/Tox Methods	5
2.3 ADME/Tox Technologies – Global Market Analysis	6
Exhibit 1. ADME/Tox Technologies – Global Market Estimations and Predictions (2005-2020) in US$ Billion	6
Exhibit 2. Major Global Companies in ADME/TOX Technologies Market	7
3. MARKET DYNAMICS	9
3.1 Market Overview	9
3.2. ADME/Tox Technologies Market	10
Global ADME/Tox Market Analysis	10
Exhibit 3. ADME/Tox Technologies – Global Market Estimations and Predictions (2005-2020) for North America, Europe, Asia-Pacific, and Rest of World in US$ Million	11
Exhibit 4. ADME/Tox Technologies – Global Market Shares (2010, 2015 & 2020) North America, Europe, Asia-Pacific, and Rest of World	12
3.3 North American ADME/Tox Market Analysis	13
Exhibit 5. ADME/Tox Technologies – North American Market Estimations and Predictions (2005-2020) for United States and Canada in US$ Million	13
Exhibit 6. ADME/Tox Technologies – North American Market Shares (20010, 2015 & 2020) for United States and Canada	14
3.3 (1) United States ADME/Tox Market	14
US Market Analysis	14
3.3 (II) Canadian ADME/Tox Market	14
Exhibit 7. List of Major ADME/Tox Companies in North America	15
3.4 European ADME/Tox Market Analysis	16
Exhibit 8. ADME/Tox Technologies – European Market Estimations and Predictions (2005-2020) for UK, Germany, France, Sweden, Finland, Italy, Russia and Rest of Europe in US$ Million	16
Exhibit 9. ADME/Tox Technologies – European Market Shares (2010, 2015 & 2020) for UK, Germany, France, Sweden, Finland, Italy, Russia and Rest of Europe	17
3.3 (1) United Kingdom ADME/Tox Market	17
UK Market Analysis	17
Major Companies in UK ADME/Tox Technologies Market	17
3.4 (II) German ADME/Tox Market	18
German Market Analysis	18
Major Companies in German ADME/Tox Technologies Market	18
3.4 (III) French ADME/Tox Market	18
French Market Analysis	18
Major Companies in French ADME/Tox Technologies Market	18
3.4 (IV) Swedish ADME/Tox Market	18
Swedish Market Analysis	18
3.4 (V) Finnish ADME/Tox Market	18
Finnish Market Analysis	18
3.4 (VI) Italian ADME/Tox Market	19
Italian Market Analysis	19
Major Companies in Italian ADME/Tox Technologies Market	19
3.4 (VII) Russian ADME/Tox Market	19
Analysis by Select Rest of Europe Countries	20
Exhibit 10. ADME/Tox Technologies – Rest of Europe Market Estimations and Predictions (2005-2020) for Switzerland, Hungary, Belgium, Austria, Spain, and Other European Countries in US$ Million	20
Exhibit 11. ADME/Tox Technologies – Rest of Europe Market Share (2010, 2015 & 2020) for Switzerland, Hungary, Belgium, Austria, Spain, and Other European Countries	21
Exhibit 12. List of Major ADME/Tox Companies in Europe	21
3.5 Asia-Pacific ADME/Tox Market Analysis	22
Exhibit 13. ADME/Tox Technologies – Asia-Pacific Market Estimations and Predictions (2005-2020) for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific in US$ Million	23
Exhibit 14. ADME/Tox Technologies – Asia-Pacific Market Shares (2010, 2015 & 2020) for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific	24
3.5 (I) Japanese ADME/Tox Market	24
Japanese Market Analysis	24
Major Companies in Japanese ADME/Tox Technologies Market	24
3.5 (II) Chinese ADME/Tox Market	24
Chinese Market Analysis	24
Major Companies in Chinese ADME/Tox Technologies Market	25
3.5 (III) Indian ADME/Tox Market	25
Major Companies in Indian ADME/Tox Technologies Market	25
3.5 (IV) Australian ADME/Tox Market	25
3.5 (V) South Korean ADME/Tox Market	26
3.5 (VI) Rest of Asia-Pacific ADME/Tox Market	26
Analysis by Select Rest of Asia-Pacific Countries	27
Exhibit 15. ADME/Tox Technologies – Rest of Asia-Pacific Market Estimations and Predictions (2005-2020) for Singapore, Hong Kong and Other Asia-Pacific Countries in US$ Million	27
Exhibit 16. ADME/Tox Technologies – Rest of Asia-Pacific Market Shares (2010, 2015 & 2020) for Singapore, Hong Kong, and Other Asia-Pacific Countries	28
Exhibit 17. List of Major ADME/Tox Companies in Asia-Pacific	28
3.6 Rest of World ADME/Tox Market Analysis	29
Exhibit 18. ADME/Tox Technologies – Rest of World Market Estimations and Predictions (2005-2020) for Brazil, South Africa, Israel and Other Countries in US$ Million	29
Exhibit 19. ADME/Tox Technologies – Rest of World Market Shares (2010,2015 & 2015) for Brazil, South Africa, Israel and Other Countries	30
Latin America	31
A few CROs operating in the Latin American Region	31
Brazilian ADME/Tox Market	31
South African ADME/Tox Market	31
Middle East	32
Israeli ADME/Tox Market	32
Exhibit 20. List of Major ADME/Tox Companies in Rest of World	32
3.7 Company Profiles - Major Players in ADME/Tox Market	33
AB Sciex (USA)	33
Accelrys, Inc. (USA)	34
Advanced Chemistry Development, Inc. (ACD Labs) (Canada)	37
Agilent Technologies, Inc. (USA)	40
Albany Molecular Research, Inc. (USA)	41
Bayer Technology Services GmbH (Germany)	42
BioFocus DPI Ltd. (UK)	43
Bio-Rad Laboratories, Inc. (USA)	44
BioreclamationIVT (USA)	48
Cellectics bioresearch (France)	50
Cerep SA (France)	51
Certara LP (USA)	53
Simcyp Ltd. (UK)	53
Tripos, Inc. (USA)	55
Charles River Laboratories International, Inc. (USA)	55
ChemSilico LLC (The) (USA)	56
Chenomx, Inc. (Canada)	57
CompuDrug International, Inc. (USA)	58
Corning, Inc. (USA)	61
Cyprotex plc (UK)	63
EMD Millipore (USA)	66
GE Healthcare Life Sciences (UK)	66
Gene Logic, Inc. (USA)	68
GenPharmTox BioTech AG (Germany)	69
Harlan Laboratories, Inc. (USA)	72
ID Business Solutions Ltd. (UK)	75
Kibron, Inc. (Finland)	76
Korea Institute of Toxicology (South Korea)	77
LHASA Ltd. (UK)	78
Life Technologies Corporation (USA)	79
Molecular Discovery Ltd. (UK)	80
MultiCASE, Inc. (USA)	82
Perkin Elmer, Inc. (USA)	83
Pharmaron (USA)	85
Promega Corporation (USA)	86
Schrodinger LLC (USA)	86
Sekisui Medical Co., Ltd. (Japan)	87
Simulations Plus, Inc. (USA)	88
Sirius Analytical Instruments Ltd. (UK)	89
Sovicell GmbH (Germany)	89
Strand Life Sciences (India)	91
Taconic Farms, Inc. (USA)	91
Tecan AG (Switzerland)	93
TetraQ (Australia)	93
Thermo Fisher Scientific, Inc. (USA)	94
Waters Corporation (USA)	96
WuXi AppTec Co., Ltd. (China)	97
Xceleron Ltd. (UK)	98
3.8 Major Activities in ADME/Tox Market	99
Charles River Laboratories Acquires the CRO Services Division of Galapagos NV	99
Simulations Plus Inks a 5-year RAC with US FDA	99
Taconic Enters into Collaboration with IVAL	99
Simulations Plus Inks a Supply Agreement with China based RILD	100
Harlan Contract Research Services and Bertin Pharma Enters into Strategic Collaboration Agreement	100
Pharmaron Gains CFDA GLP Certification for Toxicology Facility	100
Thermo Fisher Acquires Life Technologies	100
Cyprotex Acquires Business and Assets of CeeTox	101
Harlan Laboratories Plans to Locate Research Model Breeding Facility in India	101
WuXi PharmaTech Gains ADMET Predictor License	101
Taconic Signs Contract with Medicyte	101
Simulations Plus Inks Alliance with Bayer HealthCare for Improving Key Property Prediction in ADMET Predictor™	102
Bioreclamation Establishes BioreclamationIVT	102
Simulations Plus Inks MTA with NIEHS	103
AMRI and Ono Expands SMARTSOURCING™ Collaboration	103
VistaGen Therapeutics and Celsis Enter into an Alliance to Develop LiverSafe 3D	103
Calvert Labs and Particle Sciences Form Strategic Alliance to Streamline Early-Stage Drug Development	104
Xceleron Plans to Expand its Access to Powerful Analytical Platforms by Signing Partnership with JCL Bioassay	104
BD Takes Over Cato Software Solutions	104
Agilent Technologies Collaborates with Florida International University for Identification and Characterization of Designer Drugs	105
Lhasa Limited Collaborates with Optibrium	105
Mispro Biotech Services Enters into a Collaboration with The Hamner Institutes for Health Sciences	105
Hamner Institutes Enters into Association with QPS Holdings LLC	106
Accelrys ELN to Collaborate with Reaxys	106
Vivo Bio Signs Supply Agreement with Taconic for the Indian Market	107
Taconic Signs a Strategic Marketing Agreement with Yecuris	107
Charles River Laboratories Acquires Majority Ownership of Vital River	107
GVK BIO Signs Research Deal with Endo Pharmaceuticals	108
Xceleron Collaborates with Crystal Pharmatech for Advancing Early Clinical Development Employing Absolute Bioavailability Trials and Solid-State formulations	108
Elsevier Takes Over Aureus Sciences	108
Accelyrs Acquires its Partner Vialis AG	109
Charles River Takes Overs Vital River	109
Amgen is Working to Build Ultramodern Manufacturing Unit in Singapore	109
Amgen Acquires deCODE Genetics	110
Covance Receives SFDA GLP Certification for Its Early Development Facility in Shanghai, China	110
ShangPharma Corporation Inks a Definitive Merger Agreement facilitating Private Transaction	110
Medicilon Inks Alliance with Xuantai Medical	110
HitGen Enters into Strategic Partnership Agreement with Viva Biotech	111
DiscoveRx Corporation Buys BioSeek	111
NanoViricides Enters into Agreement with BASi for Toxicology and Safety Studies	112
ATTAGENE Receives New US$ 53.4 Million Contract by EPA	112
Simcyp Collaborates with US FDA	112
Corning Acquires Discovery Labware Business of BD	113
TAKEDA Inks a 3-year Drug Discovery Collaboration Agreement with ADVINUS	113
Intellect Neurosciences and iNovacia Signs Research Service Agreement	114
Charles River Laboratories and AstraZeneca Enter Strategic Partnership	114
Gentronix Signs Contract with Kowa for its First Screening Contract in Japan	114
AMRI publicizes agreement with Knopp Biosciences	114
Sigma® Life Sciences and Axiogenesis Collaborate to Market More Predictive iPSC-based Assays and Services for Preclinical Cardiotoxicity Screening	115
COARE Biotechnology and ChemDiv Enters into Co-marketing and Service Collaboration	115
BGI, GE Healthcare Collaborates on Initiating Stem Cell Science Projects	115
Affymetrix Takes Over eBioscience Holding Company, Inc.	116
Sygnature Discovery Enters into Strategic Alliance with Pneumolabs	116
ACD/Labs, Now an Associate Partner of Open PHACTS Project	116
AAIPharma Buys Celsis Analytical	117
Enamine Enters into a Partnership Agreement with UORSY	117
Luminex Corporation Extends its Life Science and Biodefense Units	118
AB SCIEX Sings New Distribution Agreement with Cluster in Serbia and Macedonia	118
AB SCIEX Extends its Business Operations in Brazil	119
Simulations Plus Buys Software Royalty Agreement with New York based Enslein Research	119
BioFocus and Argenta Enters into a Drug Discovery Collaboration Agreement with AstraZeneca	119
Jubilant Inks Drug Discovery Collaboration Agreement with Mnemosyne Pharmaceuticals	119
Covance and BioPontis Alliance Enters into Collaboration to Bridge Drug Development Gap	120
Lhasa Extends Support for “MIP-DILI”	120
Certara Acquires Simcyp	120
Lhasa Limited Inks another RCA with the FDA	121
AB SCIEX and Indigo in Collaboration to Accelerate Adoption of Next-generation Mass Spectrometry for Clinical Research, Forensic Toxicology and Clinical Trials	121
Kyorin Teams Up with BioLeap to Develop New Drug Candidates	121
NiKem Research Enters into a Strategic Partnership Agreement with Dualsystems Biotech	122
Cresset Signs a Technology Exchange Agreement with Optibrium for Enhancing Respective Drug Discovery Solutions	122
Tecan and Waters in OEM Agreement	123
ReproCell In-Licenses hIPSC-Derived Hepatocyte Screening Platform	123
Sygnature Collaborates with Cyprotex	123
Sygnature Discovery and Cyprotex Extend Successful Strategic Alliance for a Further Two Years	123
Gentronix Enters into Partnership with BioQuanta	124
Battelle in Collaboration with Molecular Imaging Enhances Drug Discovery & Development Services	124
Sygnature Discovery Join Forces with Saretius Associate to Offer Drug Discovery and Preclinical Testing Services	124
EMD Millipore to Distribute Cryopreserved HepaRG™ Terminally Differentiated Human Hepatic Cells of Biopredic	124
PerkinElmer Acquires Caliper Life Sciences	125
AB SCIEX Acquires Mass Spectrometry Division of Labindia to Expand its Presence in India	125
Cellectis Acquires Cellartis	125
ShangPharma Takes Over Shanghai In-Vivo Drug Research Facility from Charles River	126
Jubilant Biosys and Norgine to Collaborate for Finding New Drugs to Treat Gastrointestinal Diseases	126
Teva Acquires Cephalon	127
BioFocus Signs a Second Collaboration Agreement with Chiesi	127
Accelrys Collaborates with the Edge Software Consultancy	127
WuXi PharmaTech Acquires Abgent, a Major Manufacturer of Biological Research Reagents	128
GVK Biosciences Extends GOSTAR License to Astellas	128
Hamner Institutes of Health and Virginia based Investment Group Forms JV	128
Absorption Systems Collaborates with Researchers to Improve in Vitro Prediction of Pharmacokinetics	128
Alkermes Acquires Elan’s Drug Technology Business	129
ICON Signs a Contract with Bristol-Myers	129
Genentech and Argenta extend Drug Discovery Contract	129
Argenta and BioFocus Extend Drug Discovery Partnership with Genentech	130
BioFocus Collaborates with Michael J. Fox Foundation for Diagnostics for Parkinson Disease	130
Harvard Bioscience Acquires Eirus Medical, the preclinical business division of CMA	130
BioFocus Expands its Association with Usher III Initiative	130
Midas Intensifies Research Collaboration with CDI	131
Novus Biologicals Partners with Genego	131
Ricerca Biosciences Enters into Partnership with Fulcrum Pharma	131
Agilent Acquires Biocius and Lab901	132
Optiva Enters into Agreement with the US FDA to Provide Transporter Assay Services	133
QPS Acquires DCB Taiwan’s Preclinical Unit	133
Hengdu Frontier BioSciences Selects Pristima for Preclinical Data Management	134
AMRI Consolidates Global Drug Discovery Platform	134
Aureus Pharma Renamed Aureus Sciences; Launches Drug Discovery Web Portal	134
QPS Acquires India based Bioserve for Expansion Of Phase 1 and Bioanalytical Capability	135
Simulations Joins with FDA for Developing Predictive Toxicity Models	135
SRI Incorporates Subsidiary Company Sarnoff	136
BIOCIUS Life Sciences Expands Contract Research Service with New ADME Assay Analysis	136
Entelos Obtains Patent for Predictive Toxicology for Biological Systems	136
PPD and Taijitu Biologics Establishes Joint Venture for Drug Discovery of Large Molecules	137
PAREXEL and Merck in Collaboration for Clinical Development of Bio-Similar Candidates	137
Ligand Takes Over CyDex Pharmaceuticals	138
Ligand and Chiva in Strategic Drug Development Collaboration	138
ICON Buys Oxford Outcomes	138
Dow AgroSciences Partners with GVK Bio to Discover a New Lead Molecule	139
Entelos Receives Patent for Predictive Toxicology for Biological Systems	139
Ecron Acunova Signs MoU with Newcastle University	139
QIAGEN Establishes Indian Subsidiary	140
Taconic Enters Scientific Development Collaboration with BioPontis around Genetically Modified Models for Translational Research	140
Amgen and BioFocus Extends Contract until 2012	140
ADVANCELL Enters into Partnership Agreement with Gentronix	141
Vernalis Enters into Drug Discovery Collaboration with Lundbeck	141
UCSF and Pfizer in Collaboration to Improve Drug Discovery, Development	141
Selcia and Gilead Sciences Extend Liver Disease Drug Discovery Collaboration	142
Selcia in Drug Discovery Collaboration with Convergence Pharmaceuticals for Chronic Pain	142
Thomson Reuters Takes Over GENEGO	142
Life Technologies Inks Agreement with Biopredic for Generating Hepatic Cell Line	143
ACD/Labs and FDA in Development Collaboration for Predictive QSAR Models	143
Optivia and UCSF in Collaboration to Predict Liver Toxicity of Drugs in Development	143
Genstruct Adopts New Corporate Identity and Introduces a Re-branded Website	144
LGC Standards Incorporates Gentronix GreenScreen HC and BlueScreen HC to the company’s Product Portfolio	145
Southern Research Acquires BioCryst Bioanalytical Lab Unit	145
MDS Inc. Renamed Nordion Inc.,	145
Cerep and Roche Extends BioPrint® Collaboration	145
Valeant Merges with Biovail Corp	146
Evotec Completes Acquisition of DeveloGen	146
BioFocus and Usher III Initiative, Inc. in Drug Discovery Collaboration	146
AB Sciex Collaborates with the University of Melbourne for Development of Innovative Method for Drug Metabolism Studies of Biopharmaceuticals	146
The Defense Threat Reduction Agency Awards Contract to Numerate for Expansion of Drug Design Platform	147
Cyprotex Buys Stake in Apredica for Widening Services in Toxicology Market	147
NoAb BioDiscoveries and VigiCell Signs an Association and Co-Distribution Contract	148
PerkinElmer Takes Over VisEn Medical to Reinforce Cellular Imaging Service Offerings	148
Entelos Receives US Patent for Validation of Virtual Patients in a Computer Model	149
BioFocus and University of Bristol in Drug Discovery Collaboration for Chronic Pain	149
Charles River Terminates Acquisition Agreement with WuXi PharmaTech	149
AstraZeneca Consents to Drug Discovery Alliance with MRC	150
PPD and Lovelace Biomedical and Environmental Research Institute (LBERI) to Provide Laboratory, Preclinical and Clinical Research Services in Collaboration	150
LAB Research in Preferred Provider Agreement with Leading Japanese Pharmaceutical Company	150
Aptuit and Siena Biotech Enter Strategic Partnership	151
Accelrys and Symyx Technologies Completes Merger to Create Leading Scientific Informatics Software Company	151
QPS Acquires Xendo to Extend the Company Business in Europe	152
Merck KGaA, Darmstadt Acquires Millipore and Forms New EMD Millipore Division	152
Aptuit Acquires GSK’s Research Operations in Italy	152
Promega and Cellular Dynamics Collaborate to Predict Drug-Induced Cardiotoxicity by Using Stem Cell-Based In Vitro Assays	153
Entelos Signs License Agreement with Pfizer	153
CeeTox Acquires Assets of ADMETRx Inc.	153
BioSeek Inks Alliance with Eisai Co.	154
Ricerca Biosciences LLC Buys MDS Pharma Services	154
Helmholtz Centre for Infection Research (HZI) Spins out InSCREENeX GmbH	155
Gentronix Signs Three Year Contract with GlaxoSmithKline for GreenScreen HC and BlueScreen HC Genotoxicity Assays	155
Evotec Inks Alliance with Active Biotech for HTS	155
Bioseek Entered into a Two-Year Collaboration Agreement with Ono	156
CMA Microdialysis Takes Over DiLab	156
Galapagos NV Acquires Service Operations of Argenta Discovery	156
AB SCIEX Acquires Eksigent Liquid Chromatography Business	157
Shenogen and Chemizon Signs Drug Discovery Collaboration Mainly Focused on Oncology and Endocrine Disorders	157
Danaher Buys AB SCIEX and Molecular Devices	158
Celsis IVT Assigns a New Distributor in China	158
Taconic Sets Up specialized Breeding Unit in Edinburgh and Initiates transADMET Program in Association with CXR	158
Pharmaron Acquires Bridge Laboratories China	159
Asan Medical Center and Chemizon Signs Research Agreement	159
AVANZA Acquires Bridge Pharmaceuticals	159
Covance Inaugurates New Clinical Development Headquarters in South Korea and India in Addition to Office Expansion in Japan and Hong Kong	160
BioTrve Spins-off BIOCIUS Life Sciences	160
JOHCM Private Equity Acquires Celsis International plc	161
PPD Acquires BioDuro	161
Asterand Extends Collaboration Agreement with Bristol-Myers Squibb	161
Aureus Pharma Extends Knowledge Database Agreement with Sanofi-Aventis R&D	162
Roche Signs Agreement with Fluofarma	162
Maxxam Analytics Takes Over Cantest	163
Cerep Presents BioPrint® Evaluation License to Roche	163
ChemDiv’s CDRI Enters into Partnership with Viriom	163
NOTOX Teams Up WITH SRC to Offer Integrated Preclinical Services in India	164
Shanghai ChemPartner and ELARA Pharmaceuticals Elaborate Drug Discovery Cooperation to a New Level	164
Expansion of Agreement between Cellular Dynamics International and Roche Pertaining to existing Cardiotoxicity Screening	164
Asterand Signs Worldwide Research Support Agreement with Lundbeck	165
Cellular Dynamics Extends its Partnership Agreement with Roche on Cardiotoxicity Screening	165
Absorption Systems LP Acquires Stake in Perry Scientific Inc	165
Gentronix Unites with Apredica for Offering Predictive-Toxicology Based Drug Discovery Solutions	166
Cerep Enters Drug Discovery & Lead Optimization Collaboration with Servier	166
Covance Undertakes Studies on Integrated Radiolabeled Clinical Pharmacology	166
Quotient Bioresearch Acquires GE’s Amersham Radiolabelling Services	167
Quotient Bioresearch Acquires Charles River Laboratories’ Edinburgh Clinical Research Facility to Form Quotient Clinical	167
Charles River Acquires PRC for Reinforcing Oncology Service Offerings	168
BioDuro Signs Contract Research Agreement with Roche	168
Cellartis and ReproCELL Enter into Marketing Agreement to facilitate Cardiotoxicity Screening Service using hESC Derived Cardiomyocytes	168
ChemDiv’ ChemRar High Tech Center Acquires Prudentas	168
Lhasa Limited, Leadscope, Molecular Networks GmbH and Multicase Collaborate to form Insilicofirst	169
AstraZeneca Extends Discovery Contract with BioDuro	169
The Hamner and Entelos Signs Partnership Agreement	170
Entelos Signs Agreement with GlaxoSmithKline	170
Advancell Signs Agreement with ADMEcell for sales development of Cacoready™	170
ACD/Labs and Pharma Algorithms Merge	171
Solvay Inks Alliance with ChemDiv to Offer Integrated Research Solutions	171
Gene Logic Enters into Agreement with Genstruct	171
FDA Signs Agreement with Entelos to Forecast Cardiovascular Adverse Events	172
Quotient Bioscience Acquires Pharmaceutical Profiles and Elaborates Metabolic Sciences Services Offerings	172
HTG Teams Up with HC-LITT	173
Applied Biosystems and Invitrogen Merge to Form Life Technologies	173
Pfizer and WuXi PharmaTech in New Collaboration Agreement	174
Roche Enters into Collaboration Relating to ADMETRx’s Multicriteria Decision-Making Solution	174
BioTrove and Agilent Technologies Sign another Agreement giving BioTrove an Access to Agilent’s Mass Spectrometry Instruments	174
BioTrove Enters into an Exclusive Partnership with BD for Improving Effectiveness of Existing Drug Research Analysis Services	175
Charles River Buys MIR Preclinical Services	176
Sekisui America Corporation Acquires XenoTech, L.L.C.	176
Gentronix Join Forces with Abcellute to Enhance Genotoxicity Screening	176
Thermo Fisher Scientific Acquires Affinity BioReagents	177
GVK BIO and Wyeth Pharmaceuticals Signs Drug Discovery Agreement	177
MDS Analytical Technologies/Applied Biosystems Signs an Agreement with BioTrove	177
Pharmasafe in Distribution Agreement for Noraymet ADME software with NorayBio	178
Covance and WuXi PharmaTech in Joint Venture to Provide World-Class Preclinical Services in China	178
Advion BioServices to Increase Investment in Thermo Scientific’s Watson Laboratory Information Management System for Expanding Market Share in Bioanalytical Services	179
Cerep and PerkinElmer in Partnership Agreement for Custom Drug Discovery Solutions	179
Panasonic and Kalypsys to Commercialize HTS System in Collaboration in North America	180
Entelos in Research Agreement with Eli Lilly	180
XenoBiotic Laboratories, Inc. Enters into a Joint Venture with Singapore Mainboard-listed C&O Pharmaceutical Technology (Holdings) Limited	180
Agilent Technologies and Accelrys’ New OEM Agreement Increases their Areas of Cooperation	181
Azopharma Buys Analytical Development Corp.	181
Nimbus Alters its Name to Sovicell and Launches New Website	182
Ono and Evotec in New Fragment-Based Drug Discovery Agreement	182
Genedata and Bayer Expand Research Informatics Partnership	183
Cellartis and Pfizer in Research Collaboration for Development of Screening System to Detect Human Toxicity	183
Science Applications International Corporation Selects Cerep for Profiling Work on Drugs being investigated for treating Spinal Muscular Atrophy	183
Argenta Discovery Enters into Collaboration Agreement with Antisoma	184
Apptec Laboratory Services acquired by WuXi Pharmatech, a Chinese Contract Research Organization	184
Digilab Concludes acquisition of MAIA Scientific and Genomic Solutions	184
Gene Logic Divests Genomics Assets and Changes Corporate Identity	185
Chemdiv Extends Partnership Agreement with NMSI	185
Medivir Gives New Structure to Drug Discovery	186
Entelos, Inc. Agrees to Acquire Iconix Biosciences, Inc.	186
Cerep Sells Hesperion AG Business to Averion International	186
BioFocus DPI Brings Further Advancement to ADME Optimization Services	187
Symyx Technologies Closes Acquisition of MDL Information Systems	188
Simulations Plus Signs Research Agreement with Enslein	188
Acquisition of InVitro Technologies Allows Celsis to offer ADME-Tox Services	188
Gene Logic Enters into Alliance with FDA	189
Gene Logic Enters into Alliance with Solvay Pharmaceuticals to Trace New Development Channels for Multiple Clinical Drug Candidates	189
Amgen Concludes Ilypsa Acquisition	190
Waters Corporation Signs Collaborative Agreement with Umetrics AB	190
TetraQ Gains GLP Status for ADME Laboratory from NATA	190
TIBCO Acquires Spotfire Holdings	191
Waters Corporation to Collaborate with Dotmatics Limited	191
Aureus Pharma Partners with MDL® Isentris® Alliance	191
Galapagos Enters into Alliance with AstraZeneca for Novel Drug Discovery	192
Galapagos Collaborates with Ono Pharmaceutical	192
Lexicon Genetics Adopts New Corporate Identity	192
Avista Capital Acquires BioReliance Corporation	193
VASTox plc Acquires Dextra Laboratories and DanioLabs	193
Takeda Pharmaceutical Acquires Paradigm Therapeutics Limited	194
MDS Acquires Entire Stake in MDC	194
Thermo Fisher Scientific Acquires Cohesive Technologies	195
Qualyst and InterMune in B-CLEAR® Technology Licensing Deal	196
LION Bioscience Adopts New Identity	196
PerkinElmer Acquires Euroscreen Products and Evotec Technologies	196
3.9 Major Product Introductions/Developments in ADME/Tox Market	197
Simulations Plus Unveils Version 7.0 of ADMET Predictor	197
Simulations Plus Unveils ADMET Predictor™ 6.5	197
CompuDrug Introduces New Integrated Research Management System, the Laboratory Manager Plus	197
Accelrys Develops Process Management and Compliance Suite	197
BioReliance In-Licenses Rights to Big Blue® Colonies and Cell Lines from Agilent	198
Xceleron Teams Up with Kinetigen to Simplify and Advance Phase I Clinical Investigations	198
Hamner Institutes for Health Sciences Publicizes Joint Biology Initiative	199
Medicilon Inks Alliance with RILD	199
WuXi PharmaTech Joins Forces with PRA to Provide Broad Portfolio of Clinical Research Services in China	199
GE Healthcare Sublicenses Cellular Dynamics International’s Cellular Assay Patents	200
BioSeek Granted New Five-Year Contract from EPA ToxCast™ Program	200
AB SCIEX and Phytronix Improve High-Throughput Pharmaceutical Application	201
Celerion Receives Full Accreditation from AAHRPP	201
Genedata and Insilico Biotechnology Agrees to Integrate Industrial Biotechnology Platforms	202
PerkinElmer and TIBCO Software Enters into Strategic Alliance for TIBCO Spotfire® Data Visualization and Discovery in Specific Scientific Research & Development Markets	202
AB SCIEX Improves Proteomics Research with the Latest Eksigent Nano L C System	202
PharmaOptima LLC Completes Expansion	203
Woodland Oncology Services in Association with SBH Sciences Launches Preclinical Oncology Services	203
CeeTox and Cellular Dynamics Collaborates to Offer Predictive In-vitro Test for Cardiotoxicity Utilizing Human iPSC-derived Cells	203
Enamine Unites with MRC LMB and IOCB for Discovering Novel Rhomboid Protease Inhibitors as Potential Drugs	204
Celerion Expands State-Of-The Art ADME Suite in its Nebraska Facility	204
AB SCIEX Extends UHPLC Solutions Range with the Introduction of Eksigent Ekspert™ ultraLC 100 and 100-XL Systems as well as Eksigent ekspert™ microLC 200 System	205
AB SCIEX Unveils new AB SCIEX 4500 Series	205
Optibrium Launches New Version of its StarDrop™ platform	206
Quotient Enhances the new LabLogic Software	206
Cyprotex Expands US Facility	206
Caliper Launches Drug Safety Prediction and Oncology Research Platform	207
Cyprotex Enhances Cloe PK Software	207
Almac Launches rapid™	207
LabLogic introduces Version 6 of Debra LIMS for ADME studies	207
New DNA Sequencing Panel for ADME Research Released by RainDance Technologies and Ambry Genetics	208
ACD/Percepta, a new ADME software from ACD/Labs	209
Highly Effective DNA Sequencing Set Introduced by Ambry Genetics and RainDance Technologies for Research in ADME	209
Optibrium Launches StarDrop 5.1 with Apple Mac Compatibility for Enhanced Drug Discovery	210
iPLEX® ADME PGx is a New Panel from Sequenom for MassARRAY® System	210
Cyprotex Introduces Breakthrough Genomic ADME Service (gADME™)	211
AB SCIEX Extends Eksigent Chip Column Family for Nano and Micro LC Proteomics Analysis	211
Cyprotex Adds High Content Screening in Vitro Micronucleus Test	212
ActivityBase 8.0 Delivers Increased Personal Productivity and Reduced Administration	212
Promega Launches Mitochondrial ToxGlo Assay for Identification of Mitochondrial	213
Puracyp and Promega Combines Cell Lines and Assay Systems for Complete Solution for Drug Developers	213
Covance Widens Drug Metabolism Service Offerings	213
Asterand Licenses and Launches New 3-D Human Cell from Capsant	214
Absorption Systems’ Novelty in Drug Metabolism and Metabolite ID Leads to Patent Application	214
HD Biosciences Introduces Medicinal Chemistry for SAR Focused R&D Services	214
Advion BioServices Inaugurates Midwest Drug Discovery and Metabolism Center of Excellence	215
Pharsight Launches Phoenix® Software for Drug Development	215
SimuGen Launches HT-X Drug Screening Programmes	216
Entelos Successfully Gained US Patent for “Predictive Toxicology for Biological Systems”	216
Gene Logic Introduces Novel ASCENTA 4.0	217
Cyprotex Revalidates CellCiphr™ Toxicity Panels	217
Sigma Life Science Generates Globally First Knock-in Rats Utilizing Zinc Finger Nuclease Technology	218
Lhasa Introduces New Zeneth System	218
Supercomputing Research for Drug Discovery	218
ADME LIMS to Accelerate Data Reporting at QPS	219
Bio-Rad Achieves Advances in Infrared, Raman, and Polymer Spectral Interpretation	219
NOTOX Undertakes Repeated Dose Toxicity Studies in Juvenile Beagle Dogs	220
Charles River Introduces the Gentronix BlueScreen HC Genotoxicity Screening Test	220
BIOCIUS Life Sciences Expands New ADME Assay Analysis Based Contract Research Service	220
Cyprotex Launches Cloe Knowledge for Researchers	220
Simulations Introduces GastroPlus™ Version 7.0	221
Simulations Unveils MedChem Studio	221
New York State Approves CLIA DNA Test of Genelex	221
Transatlantic Adopts Common Radio-labelled ADME Platform	222
NIEHS Installs Provantis® Preclinical Software Solution	222
Cyprotex Introduces Cyprotox®, an In Vitro Toxicology Services	222
Simulations Plus Introduces Advanced Version of ADMET Predictor	223
GeneGo Launches ToxHunter Tools for Systems Toxicology Research	223
Simcyp Introduces Advanced Version of Proprietary Simulator	224
Absorption System Launches Express Plus ADME Assays	224
Pipeline Pilot™ 8.0 Launched by Accelrys	224
Agilent & BIOCIUS Launch High-Throughput, RapidFire® Accurate Mass Solution for Drug Discovery	225
Bruker Launches High Performance Mass Spectrometry Systems and Applications for Complete Bio-therapeutics Analysis	225
Optivia Introduces OptiDDITM Suite	226
Covance Sets Up an Advanced Discovery & Translational Services Unit	226
Thermo Fisher Scientific Launches New Biological Assessment Cartridges	227
Absorption Systems Incorporates Thermo Fisher’s LTQ Orbitrap XL	227
Lablogic Introduces New Version of LIMS	228
Caliper Life Sciences Introduces Quantum FX microCT System - a New Modality for Pre-Clinical Imaging	228
Illumina Launches VeraCode(R) ADME Core Panel	228
MCM Employs Provantis Preclinical Software Solution	229
Cellartis Launches Novel 2D Cardiomyocyte Product	229
Quotient Bioresearch Expands In Vitro Services	229
Entelos and RegeneMed Launches iToxFX to Facilitate the Prediction of New Drugs Safety	230
Sigma-Aldrich to Offer Knockout Rats for ADME/Tox	230
SIGMA Launches World's First Suite of Knockout Rats for ADME/Tox Applications	231
Advion BioSystems Introduces a New LESA Sample Analysis System	231
Gentronix Introduces Bluescreen HC and Expands Comet Assay Testing Based Services	231
PharmaDiagnostics Launches SoPRano™ Range of Screening Products and Services	232
LGC Standards Adds Extra Drug Discovery Tools	232
Hudson Robotics Launches New ADME-Tox Screening System	233
XBL Advances QWBA and Cryo-Imaging Services	233
New Drug Metabolism Assays Launched by Absorption Systems	233
XenoTech Launches CryostaX™, an Innovative Single-Freeze Source for Human Hepatocytes	234
Cellumen Discovers in vitro Rat Hepatocyte Early Safety Assessment Panel for DILI predictivity	234
NiKem Obtains Italian GLP Certification for Bio-Analysis Facility	234
BioWisdom Introduces Safety Intelligence Program (Version 3.0)	235
Advion BioServices enhances the LC/MS Biomarker Service Unit	235
Aureus Pharma Launches DDI Predict 2009 Edition	236
Expansion of Cytotoxic and ADME Services by Wolfe Laboratories	236
RapidFire® Granted CE Mark, First System in Europe Installed at Boehringer Ingelheim	236
Eksigent Declares Major Development for HPCL Manufacturing and Service	237
Covance expands Service Capacity and Expertise for Metabolite Identification	237
Advancell Launches Cellular Reagent Isocyp-Tox™, for Hepatic Toxicity Prediction	238
New Mass Spectrometry Solution Cliquid® MPX™-2 Launched by Applied Biosystems and MDS Analytical Technologies	238
Thermo Fisher Scientific Launches Thermo Scientific Cellomics ToxInsight Solution for In Vitro Toxicity Testing	238
BD Biosciences Releases BD UltraPool™ HLM 150 Reagent	239
Standardized and Cost-Efficient Drug Metabolizing Enzymes and Transporters (DMET) Analysis Services Launched Globally by Cogenics	239
BioTrove Launches RapidFire 300 for In-vitro ADME Screening	240
TTP LabTech Launches Acumen® eX3	240
XBL Enhances Key Services	240
Nikem Expands ADMET and In-vivo Assay Capabilities	241
Millipore Corporation and CXR Biosciences Launches Toxicity Reporter Assay Panel	241
Applied Biosystems/MDS Analytical Technologies Launches New Version of DiscoveryQuant™ Software	241
BioFocus Strengthens ADME/PK Laboratory Bioanalytical Capabilities	242
BioWisdom Unveils Version 2 of KnowledgeScan and contracts with BTG to Provide to Enhanced Solutions	242
Cresset BioMolecular Discovery Releases FieldStere	243
Bio-Rad Incorporates Automatic Filtering of NMR Spectra (AFNS) of University of Wisconsin-Madison in to KnowItAll® Metabolomics Software	243
Eksigent Launches ExpressHT™-Ultra HPLC System	243
Bio-Rad Launches Latest Infrared and UV-Vis Spectral Databases	244
Aptuit Introduces Program to Accelerate Early Stage Drug Development	244
Thermo Fisher Scientific Launches ToxSpec Analyzer	244
Simcyp Introduces Virtual ‘Lab Rat’	245
PerkinElmer Launches GMP Compliant Radiolabeling Services for Drug Candidate Screening	245
BioFocus DPI Opts for BioBook to Manage ADME Data	246
ADME LIMS Suitable for Unlabelled Compound Data	246
Assay Depot Introduces Online Drug Discovery Services	246
Ariadne Introduces Pathway Studio® Version 6	247
FDA Licenses ADMET Predictor™ from Simulations Plus	247
Leadscope Launches FDA QSAR Toxicity Models	247
US Patent Grants for Gene Expression Based Liver Toxicity Screening Test	248
ADME LIMS to Monitor Sampling Time Deviations	248
New Technology Employed in ADMET Predictor™ 3.0 for Molecular Descriptors	248
CXR Biosciences and Millipore Corporation Launch New Antibody Panel	249
Xceleron’s New Research Laboratory in Maryland, USA Starts Operations	249
Gwathmey Launches Cardionomics™ Services for Preclinical Cardiac Safety Screening of Drug Candidates	250
Cyprotex Launches New Catalogue for Experimental and Predictive ADME and PK Services	250
Simcyp Launches Version 8.0 of Simcyp Population-based ADME Simulator	251
Cyprotex Launches Cloe® Select	251
Simcyp Launches Latest Version of Pediatric ADME Simulator	251
BioFocus DPI Introduces ADME/PK Laboratory Services and StarDrop™ Software Solution	252
Novel Assay-Specific Human Liver Microsomes Launched by Celsis In Vitro Technologies	252
Abacalab Launches Chemistry Labacus (R) Version 2.1	253
Pharma Algorithms Releases New ADME Boxes Version 4.0	253
Simulations Plus Releases New Important Upgrade of ClassPharmer™ Software	253
Applied Biosystems and Sciex Jointly Launch the New Cliquid™ Drug Screen and Quant Software for Application in Routine Forensic Toxicology	254
BioReliance Introduces Novel Genotoxicity Screening Service	254
Caliper Life Sciences Introduces CDAS for Offering Complete Drug Discovery and Development Services	255
Simulations Plus Introduces New DNA Mutation Predictor	256
Simulations Plus Launches ADMET Predictor™ Version 2.3	256
Pharma Algorithms Announces ToxBox Version 2.0	256
Aureus Pharma Introduces New Tool to Identify Risks of Drug-Drug Interactions	257
DTEx™ - New technology for Gene Expression Profiling for Drugs	257
Strand Introduces New Platform for In Silico Lead Optimization	258
NMS Introduces the New Brand Accelera	258
3.10 In Vivo ADME/Tox – An Ever Growing Technology	259
Global In Vivo ADME/Tox Market Analysis	259
Exhibit 21. In Vivo ADME/Tox Technologies– Global Market Estimations and Predictions (2005-2020) for North America, Europe, Asia-Pacific, and Rest of World in US$ Million	260
Exhibit 22. In Vivo ADME/Tox Technologies – Global Market Shares (2010,2015 & 2020) for North America, Europe, Asia-Pacific, and Rest of World	261
Exhibit 23. List of Global In Vivo ADME/Tox Companies	261
3.10.2 North American In Vivo ADME/Tox Market Analysis	263
Exhibit 24. In Vivo ADME/Tox Technologies– North American Market Estimations and Predictions (2005-2020) for United States and Canada in US$ Million	263
Exhibit 25. In Vivo ADME/Tox Technologies – North American Market Shares (2010, 2015 & 2020) for United States, and Canada	264
3.10.2 (1) United States In Vivo ADME/Tox Market	264
3.10.2 (1I) Canadian In Vivo ADME/Tox Market	264
3.10.3 European In Vivo ADME/Tox Market Analysis	265
Exhibit 26. In Vivo ADME/Tox Technologies– European Market Estimations and Predictions (2005-2020) for UK, Germany, France, Sweden, Finland, Italy, Russia and Rest of Europe in US$ Million	265
Exhibit 27. In Vivo ADME/Tox Technologies – European Market Shares (2010, 2015 & 2020) for UK, Germany, France, Sweden, Finland, Italy, Russia and Rest of Europe	266
3.10.3 (1) United Kingdom In Vivo ADME/Tox Market	266
3.10.3 (II) German In Vivo ADME/Tox Market	266
3.10.3 (III) French In Vivo ADME/Tox Market	266
3.10.3 (IV) Swedish In Vivo ADME/Tox Market	266
3.10.3 (V) Finnish In Vivo ADME/Tox Market	267
3.10.3 (VI) Italian In Vivo ADME/Tox Market	267
3.10.3 (VII) Russian In Vivo ADME/Tox Market	267
3.10.4 Asia-Pacific In Vivo ADME/Tox Market	268
Exhibit 28. In Vivo ADME/Tox Technologies– Asia-Pacific Market Estimations and Predictions (2005-2020) for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific in US$ Million	268
Exhibit 29. In Vivo ADME/Tox Technologies – Asia-Pacific Market Shares (2010, 2015 & 2015) for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific	269
3.10.4 (1) Japanese In Vivo ADME/Tox Market	269
3.10.4 (II) Chinese In Vivo ADME/Tox Market	269
3.10.4 (III) Indian In Vivo ADME/Tox Market	269
3.10.4 (IV) Australian In Vivo ADME/Tox Market	269
3.10.4 (V) South Korean In Vivo ADME/Tox Market	269
3.10.5 Rest of World In Vivo ADME/Tox Market	270
Exhibit 30. In Vivo ADME/Tox Technologies– Rest of World Market Estimations and Predictions (2005-2020) for Brazil, South Africa, Israel, and Other Countries in US$ Million	270
Exhibit 31. In Vivo ADME/Tox Technologies– Rest of World Market Shares (2010, 2015 & 2020) for Brazil, South Africa, Israel, and Other Countries	271
3.10.5 (1) Brazilian In Vivo ADME/Tox Market	271
3.10.5 (III) South African In Vivo ADME/Tox Market	271
3.10.5 (II) Israeli In Vivo ADME/Tox Market	271
3.11 In Vitro ADME/Tox – An Emerging Technology	272
3.11.1 Global In Vitro ADME/Tox Market Analysis	272
Exhibit 32. In Vitro ADME/Tox Technologies – Global Market Estimations and Predictions (2005-2020) for North America, Europe, Asia-Pacific, and Rest of World in US$ Million	273
Exhibit 33. In Vitro ADME/Tox Technologies – Global Market Shares (2010, 2015 & 2020) for North America, Europe, Asia-Pacific, and Rest of World	274
Exhibit 34. List of Major Global In Vitro ADME/Tox Companies	274
3.11.2 North American In Vitro ADME/Tox Market Analysis	277
Exhibit 35. In Vitro ADME/Tox Technologies– North American Market Estimations and Predictions (2005-2020) for United States and Canada in US$ Million	277
Exhibit 36. In Vitro ADME/Tox Technologies – North American Market Shares (2010,2015 & 2020) for United States, and Canada	278
3.11.2 (I) United States In Vitro ADME/Tox Market	278
3.11.2 (I1) Canadian In Vitro ADME/Tox Market	278
3.11.3 European In Vitro ADME/Tox Market	279
Exhibit 37. In Vitro ADME/Tox Technologies– European Market Estimations and Predictions (2005-2020) for UK, Germany, France, Sweden, Finland, Italy, Russia and Rest of Europe in US$ Million	279
Exhibit 38. In Vitro ADME/Tox Technologies – European Market Shares (2010, 2015 & 2020) for UK, Germany, France, Sweden, Finland, Italy, Russia and Rest of Europe	280
3.11.3 (1) United Kingdom In Vitro ADME/Tox Market	280
3.11.3 (II) German In Vitro ADME/Tox Market	280
3.11.3 (III) French In Vitro ADME/Tox Market	280
3.11.3 (IV) Swedish In Vitro ADME/Tox Market	280
3.11.3 (V) Finnish In Vitro ADME/Tox Market	281
3.11.3 (VI) Italian In Vitro ADME/Tox Market	281
3.11.3 (VII) Russian In Vitro ADME/Tox Market	281
3.11.4 Asia-Pacific In Vitro ADME/Tox Market	282
Exhibit 39. In Vitro ADME/Tox Technologies– Asia-Pacific Market Estimations and Predictions (2005-2020) for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific in US$ Million	282
Exhibit 40. In Vitro ADME/Tox Technologies – Asia-Pacific Market Shares (2010, 2015 & 2015) for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific	283
3.11.4 (I) Japanese In Vitro ADME/Tox Market	283
3.11.4 (II) Chinese In Vitro ADME/Tox Market	283
3.11.4 (III) Indian In Vitro ADME/Tox Market	283
3.11.4 (IV) Australian In Vitro ADME/Tox Market	283
3.11.4 (V) South Korean In Vitro ADME/Tox Market	283
3.11.5 Rest of World In Vitro ADME/Tox Market	284
Exhibit 41. In Vitro ADME/Tox Technologies– Rest of World Market Estimations and Predictions (2005-2020) for Brazil, South Africa, Israel and Other Countries in US$ Million	284
Exhibit 42. In Vitro ADME/Tox Technologies– Rest of World Market Shares (2010, 2015 & 2020) for Brazil, Israel, South Africa, and Other Countries	285
3.11.5 (1) Brazilian In Vitro ADME/Tox Market	285
3.11.5 (III) South African In Vitro ADME/Tox Market	285
3.11.5 (II) Israeli In Vitro ADME/Tox Market	285
3.12 In Silico ADME/Tox – The Fastest Growing Technology	286
3.12.1 Global In Silico ADME/Tox Market	286
Exhibit 43. In Silico ADME/Tox Technologies – Global Market Estimations and Predictions (2005-2020) for North America, Europe, Asia-Pacific, and Rest of World in US$ Million	287
Exhibit 44. In Silico ADME/Tox Technologies – Global Market Shares (2010, 2015 & 2020) for North America, Europe, Asia-Pacific, and Rest of World	288
Exhibit 45. List of Major Global In Silico ADME/Tox Companies	288
3.12.2 North American In Silico ADME/Tox Market Analysis	289
Exhibit 46. In Silico ADME/Tox Technologies– North American Market Estimations and Predictions (2005-2020) for United States and Canada in US$ Million	289
Exhibit 47. In Silico ADME/Tox Technologies – North American Market Shares (2010, 2015 & 2020) for United States, and Canada	290
3.12.2 (1) United States In Silico ADME/Tox Market	290
3.12.2 (II) Canadian In Silico ADME/Tox Market	290
3.12.3 European In Silico ADME/Tox Market	291
Exhibit 48. In Silico ADME/Tox Technologies– European Market Estimations and Predictions (2005-2020) for UK, Germany, France, Sweden, Finland, Italy, Russia and Rest of Europe in US$ Million	291
Exhibit 49. In Silico ADME/Tox Technologies – European Market Shares (2010, 2015 & 2020) for UK, Germany, France, Sweden, Finland, Italy, Russia and Rest of Europe	292
3.12.3 (I) United Kingdom In Silico ADME/Tox Market	292
3.12.3 (II) German In Silico ADME/Tox Market	292
3.12.3 (III) French In Silico ADME/Tox Market	292
3.12.3 (IV) Swedish In Silico ADME/Tox Market	292
3.12.3 (V) Finnish In Silico ADME/Tox Market	293
3.12.3 (VI) Italian In Silico ADME/Tox Market	293
3.12.3 (VII) Russian In Silico ADME/Tox Market	293
3.12.4 Asia-Pacific In Silico ADME/Tox Market	294
Exhibit 50. In Silico ADME/Tox Technologies– Asia-Pacific Market Estimations and Predictions (2005-2020) for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific in US$ Million	294
Exhibit 51. In Silico ADME/Tox Technologies – Asia-Pacific Market Shares (2010, 2015 & 2020) for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific	295
3.12.4 (I) Japanese In Silico ADME/Tox Market	295
3.12.4 (II) Chinese In Silico ADME/Tox Market	295
3.12.4 (III) Indian In Silico ADME/Tox Market	295
3.12.4 (IV) Australian In Silico ADME/Tox Market	295
3.12.4 (V) South Korean In Silico ADME/Tox Market	295
3.12.5 Rest of World In Silico ADME/Tox Market	296
Exhibit 52. In Silico ADME/Tox Technologies– Rest of World Market Estimations and Predictions (2005-2020) for Brazil, South Africa, Israel, and Other Countries in US$ Million	296
Exhibit 53. In Silico ADME/Tox Technologies– Rest of World Market Shares (2010, 2015 & 2020) for Brazil, South Africa, Israel, and Other Countries	297
3.13 Related Technologies	298
3.13.1 Laboratory Information Management Systems	298
Exhibit 54. Laboratory Information Management System (LIMS) – Global Market Estimations and Predictions (2005-2020) in US$ Million	298
3.13.2 High Throughput Screening	299
3.13.2.1 Global HTS Market	299
Exhibit 55. High Throughput Screening (HTS) – Global Market Estimations and Predictions (2005-2020) in for United States, Europe, Asia-Pacific, Canada and Rest of World US$ Million	300
Exhibit 56. High Throughput Screening (HTS) – Global Market Shares (2010, 2015 & 2020) for North America, Europe, Asia-Pacific and Rest of World	301
US Market for High Throughput Screening (HTS)	301
Canadian Market for HTS	301
European Market for HTS	301
Asia-Pacific Market for HTS	301
3.13.2.2 Global HTS Products Market	302
Exhibit 57. HTS Products – Global Market Estimations and Predictions (2005-2020) in US$ Million	302
3.13.2.3 Global Market for Re-Screening of Hits	303
Exhibit 58. Re-Screening of Hits – Global Market Estimations and Predictions (2005-2020) in US$ Million	303
3.13.2.4 Global Market for HTS Services and Consumables	304
Exhibit 59. HTS Services and Consumables – Global Market Estimations and Predictions (2005-2020) in US$ Billion	304
3.13.2.5 Global Market for HTS Services and Cell Based Consumables	305
Exhibit 60. HTS Services and Cell Based Consumables – Global Market Estimations and Predictions (2005-2020) in US$ Billion	305
3.13.2.6 Global Spending on HTS for Lead Discovery	306
Exhibit 61. Spending on HTS for Lead Discovery – Global Market Estimations and Predictions (2005-2020) for United States, Europe, and Rest of World in US$ Billion	306
3.13.2.7 US Spending on HTS for Lead Discovery	307
Exhibit 62. Spending on HTS for Lead Discovery- United States Market Estimations and Predictions (2005-2020) in US$ Billion	307
3.13.2.8 European Spending on HTS for Lead Discovery	308
Exhibit 63. Expenditure on HTS for Lead Discovery – European Market Estimations and Predictions (2005-2020) in US$ Billion	308
3.13.3 Cell Based Assays	309
3.13.3.1 Global Market for Cell Based Assays	309
Exhibit 64. Cell-Based Assays – Global Market Estimations and Predictions (2005-2020) for United States, Europe, Asia-Pacific, Canada and Rest of World in US$ Million	310
Exhibit 65. Cell-Based Assays – Global Market Shares (2010,2015 & 2020) for United States, Europe, Asia-Pacific, Canada and Rest of World	311
US Market for Cell Based Assays	311
Canadian Market for Cell Based Assays	311
European Market for Cell Based Assays	311
3.13.3.2 Global Pharmaceutical Cell Based Screening Market	312
Exhibit 66. Pharmaceutical Cell-Based Screening – Global Market Estimations and Predictions (2005-2020) in US$ Billion	312
3.13.4 Global Drug Discovery Market	313
3.13.4.1 Global Drug Discovery Expenditure	313
Exhibit 67. Drug Discovery Expenditure – Global Market Estimations and Predictions (2005-2020) in US$ Billion	314
3.13.4.2 US Market for Pharma Contract Research	315
Exhibit 68. Pharmaceutical Contract Research – United States Market Estimations and Predictions (2005-2020) in US$ Billion	315
Exhibit 69. Number of Approved Drugs in the United States as of 2013	316
3.13.4.3 European Market for Drug Discovery	317
Exhibit 70. Drug Discovery – European Market Estimations and Predictions (2005-2020) in US$ Billion	317
3.13.4.4 European Market for Drug Discovery Outsourcing	318
Exhibit 71. Drug Discovery Outsourcing – European Global Market Estimations and Predictions (2005-2020) in US$ Billion	318
3.13.4.5 European Market for Nanotechnology Based Drug Discovery	319
Exhibit 72. Drug Discovery Based on Nanotechnology – European Market Estimations and Predictions (2005-2020) in US$ Billion	319
3.13.4.6 Asia-Pacific Market for Drug Discovery	320
Drug Discovery Scenario in Asia-Pacific	320
Exhibit 73. Drug Discovery– Asia-Pacific Market Estimations and Predictions (2005-2020) in US$ Billion	321
3.13.4.7 Asia-Pacific Market for Pharma CROs	322
Exhibit 74. Pharmaceutical Contract Research Organization – Asia-Pacific Market Estimations and Predictions (2005-2020) in US$ Billion	322
3.13.5 Global Biotech Industry at a Glance	323
3.13.5.1 Major Research Areas in Biotechnology	324
Exhibit 75. Global Biotechnology Industry (2012): Percentage Breakdown of Major Research Areas	324
3.13.5.2 Canadian Market for Biotech R&D	325
Exhibit 76. Biotechnology R&D Expenditure – Canadian Market Estimations and Predictions (2005-2020) in US$ Billion	325
3.13.5.3 European Biotechnology Market	326
Exhibit 77. Biotechnology R&D Expenditure – European Market Estimations and Predictions (2005-2020) in US$ Billion	327
3.14 ADME/Tox Technologies – Market Outlook	328
Key Market Challenges	328
Other Side of the Coin	329
Key Market Drivers	330
4. PRODUCT/TECHNOLOGY RESEARCH	331
4.1 Introduction	331
ADME/Tox – The Basics	331
Absorption	332
Distribution	332
Metabolism	332
Excretion	332
Toxicity	333
Factors Determined by ADME/Tox	333
ADME/Tox Properties are Determined by -	333
The Increasing Need to Predict ADME/Tox Profiles	334
Preclinical ADME/Tox Evaluation Tools	335
Some of the Current Evaluation Tools for ADME/Tox in Use Include –	335
Preclinical ADME/Tox Tools are generally validated for –	336
4.2 ADME/Tox – Essence of Pharmaceutical Industry	337
Drug Development - An Overview	338
Origin and Development of New Chemical Entity (NCE)	338
Process of Drug Development	339
Target Identification	339
Target Validation	339
Lead Identification	339
Technologies for Lead Generation	340
Common Technologies for Lead Generation Include -	340
Lead Optimization	340
Preclinical Trials	340
Technologies for Preclinical Development of Drug Candidates	341
Clinical Trials	341
Phase I	341
Phase II	341
Phase III	342
Exhibit 78. Drug Development Cost - Estimations and Predictions (2005-2020) in US$ Million	342
Major hurdles in drug development process are:	343
Stages of Drug Development	344
Exhibit 79. Critical Path for a Drug to Enter Clinical Trials	344
Improved Technology Infrastructure Increases Potential of Manufacturing Efficiency	345
Exhibit 80. Estimated Time Required for Development of Drugs by Primary Indication (In Years)	346
4.3 ADME/Tox in Drug Discovery Process	347
Factors Influencing Drug Approval Rates	347
Ideally, a successful DMPK drug -	347
Estimating Potential R&D Efficiency Gains from an Improved Technology Infrastructure	348
Reasons for the Decline in Success Rates	348
Exhibit 81. Reasons for Drug Failure in Clinical Trials Phase I – III	349
4.4 ADME/Tox Methods	350
Predictive Technologies	350
Overlapping of Predictive ADME/Tox Technologies	350
Applications by Technology	350
Exhibit 82. Overlapping of Predictive ADME/Tox Technology Applications across Various Stages of Drug Discovery	350
Importance of In Vivo Tests	351
Exhibit 83. In Vivo ADME/Tox Methods	351
Modern In Vivo ADME/Tox Models	351
Zebrafish	351
Rodent Models	352
Drosophila	352
C.elegans	352
Conventional In Vivo ADME/Tox Models	352
Radiolabels	352
Cassette Dosing	352
Semi Simultaneous Dosing	352
Why do we Need Animals for Trials?	352
In Vitro ADMET	353
In Vitro Assays	353
Veterinary In Vitro Testing	353
Exhibit 84. Veterinary In Vitro Testing Technologies – Global Market Estimations and Predictions (2005-2020) in US$ Million	354
In Vitro Applications for Drug Discovery and Development	355
Human and Animal Metabolism	355
Permeation Studies	355
Other ADME Services	355
Exhibit 85. In Vitro ADME/TOX Methods	355
Examples of Human in Vitro ADME/Tox Assays Include	356
Biological Assay Systems for the Evaluation of Cytochrome P450 Enzyme Isoforms	357
In Silico ADMET	357
In Silico Applications along Preclinical Stages	358
In Silico Predictive Models	358
Broad Segmentation of In Silico Technology	358
Analysis by Segment	359
Exhibit 86. In Silico ADME/Tox – Global Value Market Estimations and Predictions (2005-2020) for Organ and Tissue Cells, Cellular Networks, and Whole Cells in US$ Million	359
Applications of In Silico Models in Drug Discovery Process	360
Potential Applications of In Silico Technology	360
Prediction of In Silico Profiles by Metabolic Behavior	360
In Silico Technologies – Market Scenario	360
Prospects	360
Constraint	360
Related Technologies	361
Screening Technologies	361
The various types of screening technologies include	361
High Throughput Screening	361
Primary Screening	362
Secondary Screening	363
Biochemical Assays	364
Cell based Assays	364
High Content Screening	364
4.5 Toxicity	364
Toxicity – An Overview	364
Exhibit 87. Percentage of Toxicities Leading to Drug Failures in Clinical Trials (Phase I-III)	365
Toxicology - Reason for Drug Failure	365
Preclinical Toxicology	367
Predictive Toxicology	367
Methods and Challenges Involving Predictive Toxicology in Drug Discovery & Development	367
“Rule of Five”	368
ADME/Tox Models (Statistical Significance / Mechanistic Interpretation)	368
Challenges of ADME/Tox Prediction	369
Determining Factors for Effective Predictive Toxicology in Preclinical Stage	369
Remedial Measures	370
Types of Toxicities	370
Exhibit 88. Common Types of Toxicity Targeted for ADME/TOX Predictive Techniques	370
Hepatotoxicity or Drug Induced Liver Injury (DILI)	371
Metabolism of Drugs	371
Metabolism of Drug in Liver	371
Factors Resulting in Liver Damage	372
Drug Response	372
Future Prospects	373
Cardiotoxicity	373
Diagnosis	373
Cardiovascular Toxicity and QT Prolongation	374
Nephrotoxicity	374
Diagnosis	375
Neurotoxicity	375
Pulmonary Toxicity	376
Diagnosis	377
Pulmonary Toxicity Due to Medicinal Drugs	377
Pulmonary Toxicity Due to Radiation (Radiotherapy)	377
Pulmonary Toxicity Due to Chemical Compounds	377
Pulmonary Toxicity Due to Particulate Matter (cars, industry, etc)	378
Myotoxicity or Muscle Related Diseases	378
Dermatoxicity or Skin Related Allergies	378
Phototoxicity	378
Oculotoxicity	379
Reproductive Toxicity	379
Genotoxicity	380
Ames Testing to Confirm Genotoxicity	380
Genotoxicity and its Serious Impact on Regulatory Agencies	381
Hematotoxicity	381
Carcinogenicity	381
Cytotoxicity	381
Torsades de pointes	382
Exhibit 89. Common Approved In Vitro and In Vivo Procedures	382
Types of Predictive Toxicology	382
Computational Toxicology	382
QSAR	383
In Vitro Toxicology	383
Exhibit 90. Non-animal Methods being Considered for Validation	383
In Vitro Toxicology – Liver Cell Models	383
Tissue Culture Systems Used in In Vitro Toxicology	384
In Vitro Toxicology Applications	384
Genomics in Toxicity Testing	384
Examining Neurotoxicity	385
Alternatives for Animals in Toxicity Testing	386
Exhibit 91. Common Animals Used for ADME and Toxicity Testing	386
Exhibit 92. In vivo Animal Models for Toxicity Tests and their Importance	386
4.6 ADME/TOX and Drug Discovery Technologies	387
Pharmacogenomics	387
Pharmacokinetics	388
LADMET-R and Pharmacokinetics	389
ADME Associated Proteins	390
A – Category	390
D – Category	390
M – Category	390
E – Category	391
Exhibit 93. Classification of Protein Targets by Category	391
Proteomics	392
Bioinformatics	392
Challenges Facing the ADME/Tox Industry	392
4.7 ADME/TOX Technologies – Research Briefs	394
Computing toxic chemicals	394
Faster smarter and cheaper drug discovery	395
Novel drug –screening process gives long sought anti-HIV compounds-Potential drugs acts on target that are not likely to mutate	395
Validation of the Preclinical efficacy of the TB drug target	397
Genomics of ADME	397
The edge of the drug development	397
Pharmacogenetics Testing Provides Way to Decrease Deaths Caused by Drug Toxicity	398
A computer/test tube combination provides the best drug developments results ever	398
Comprehensive study indicating better time frame of a drug remaining in its target (residence time) leads to enhanced therapeutic and diagnostic agents	399
Drug Metabolism Interaction of Enzymes and its Significance to Toxicity and Effectiveness	400
Zebrafish the latest entrant in the drug Development process	400
Novel methods in the development of Functional Hepatocytes explored by Scientists	402
The protocol to eliminate costly missteps in the process of drug development	403
Avoiding Expensive Missteps in Developing Drugs	403
MetaChip introduce rapid and effective toxicity screening protocol for potential drugs	404
5. CORPORATE DIRECTORY	406
6. PATENTS INFORMATION	434

To request a free sample copy of this report, please complete the form below.

Enter captcha code*

We never share your personal data. Privacy policy